• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Efficacy of Deep Brain Stimulation for OCD
Research Update

Efficacy of Deep Brain Stimulation for OCD

November 1, 2023
John Raiss, MD
From The Carlat Child Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

John Raiss, MD. Dr. Raiss has no financial relationships with companies related to this material.

REVIEW OF: Weinzimmer SA et al, J Child Adolesc Psychopharmacol 2021;31(2):109–117 

TYPE OF STUDY: Opinion study

Parents often ask about deep brain stimulation (DBS) for their children with obsessive-compulsive disorder (OCD). But are there data to support this invasive treatment? DBS is established for treatment-resistant Parkinson’s disease, essential tremor, and dystonia, as well as an investigational OCD treatment for patients over 18. DBS is thought to inhibit overactive brain networks by delivering electrical stimulation to specific brain regions from a pulse generator implanted in the chest wall. Stimulation levels are adjusted every two weeks to optimize results, which can take up to 12 months. While multiple target sites have been used, it is unclear which ones are superior. 

Side effects include surgical and hardware complications (eg, infection, hemorrhage, seizure, device migration and malfunction). There are alsocomplications. If DBS abruptly ceases, the patient can experience severe increases in depression, hypomania, anxiety, obsessions, compulsions, sleep problems, suicidal behavior, and suicide (Martinho FP et al, J Clin Psychiatry 2020;81(3):19r12821).

DBS is not currently recommended outside of research settings. It is contraindicated in patients under 18, in part because long-term follow-up studies show that most young OCD patients improve with time (Scoog G and Scoog I, Arch Gen Psychiatry 1999;56(2):121–127). In addition, two large, randomized, double-blinded, multicenter trials in adults failed to support the use of DBS for refractory major depression (Holtzheimer PE et al, Lancet Psychiatry 2017;4(11):839–849; Dougherty DD et al, Biol Psychiatry 2015;78(4):240–248). Despite this information, new research suggests that there is a consumer desire to use DBS to help children and adolescents with OCD.

In a recent industry-influenced opinion study, 260 participants, ages 18–65, mostly recruited at an international OCD conference, completed a questionnaire about their views on the use of DBS in adolescents with severe OCD. Of the participants, 106 had a history of OCD, 123 had a child with OCD, and 31 had both their own OCD history and a child with OCD. In total, 63% rated DBS positively (7 points or higher on a 0–10 Likert scale of acceptability from “totally unacceptable” to “totally acceptable”); only 15% found DBS unacceptable, rating it as 4 or lower. Participants would be most willing to endorse the use of DBS if a child had suicidal ideation, and if assurances were given that daily functioning would improve and symptoms would be greatly reduced. Worries about safety and harm to brain or body were associated with reluctance in endorsing use of DBS. Participants’ personal experience with OCD or their own child’s OCD symptom severity did not affect their views about DBS.

Most respondents were favorably disposed to this invasive experimental treatment, despite the disappointing data for DBS in treating depression in adults and lack of data for OCD. One of the study authors is a consultant for DBS device manufacturers (Medtronic, Boston Scientific).

Carlat Take 

Counsel parents against the use of invasive treatments with little supportive evidence and many potential side effects, and work with them to pursue competent and complete trials of proven treatments.

Child Psychiatry Research Update
KEYWORDS adolescents children efficacy obsessive compulsive disorder ocd
    John Raiss, MD

    Consider Catatonia in Your Differential

    More from this author
    www.thecarlatreport.com
    Issue Date: November 1, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Obsessive Compulsive Disorder in Children and Adolescents, CCPR, October/November/December 2023
    Note From the Editor-in-Chief
    Lithium for Children and Adolescents
    Treating OCD With Co-Occurring Conditions
    Basics of Office-Based CBT for OCD
    Tapering Antipsychotics
    Efficacy of Deep Brain Stimulation for OCD
    CME Post-Test, Obsessive Compulsive Disorder in Children and Adolescents, CCPR, October/November/December 2023
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.